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Abstract
Background: Aberrant expression of myeloid antigens (MyAgs) on acute lymphoblastic leukemia (ALL) cells is
a well-documented phenomenon, although its regulating mechanisms are unclear. MyAgs in ALL are interpreted
e.g. as hallmarks of early differentiation stage and/or lineage indecisiveness. Granulocytic marker CD66c –
Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is aberrantly expressed on ALL with
strong correlation to genotype (negative in TEL/AML1 and MLL/AF4, positive in BCR/ABL and hyperdiploid
cases).
Methods: In a cohort of 365 consecutively diagnosed Czech B-precursor ALL patients, we analyze distribution
of MyAg+ cases and mutual relationship among CD13, CD15, CD33, CD65 and CD66c. The most frequent MyAg
(CD66c) is studied further regarding its stability from diagnosis to relapse, prognostic significance and regulation
of surface expression. For the latter, flow cytometry, Western blot and quantitative RT-PCR on sorted cells is
used.
Results: We show CD66c is expressed in 43% patients, which is more frequent than other MyAgs studied. In
addition, CD66c expression negatively correlates with CD13 (p < 0.0001), CD33 (p = 0.002) and/or CD65 (p =
0.029). Our data show that different myeloid antigens often differ in biological importance, which may be
obscured by combining them into "MyAg positive ALL". We show that unlike other MyAgs, CD66c expression is
not shifted from the onset of ALL to relapse (n = 39, time to relapse 0.3–5.3 years). Although opposite has
previously been suggested, we show that CEACAM6 transcription is invariably followed by surface expression (by
quantitative RT-PCR on sorted cells) and that malignant cells containing CD66c in cytoplasm without surface
expression are not found by flow cytometry nor by Western blot in vivo. We report no prognostic significance
of CD66c, globally or separately in genotype subsets of B-precursor ALL, nor an association with known risk
factors (n = 254).
Conclusion: In contrast to general notion we show that different MyAgs in lymphoblastic leukemia represent
different biological circumstances. We chose the most frequent and tightly genotype-associated MyAg CD66c to
show its stabile expression in patients from diagnosis to relapse, which differs from what is known on the other
MyAgs. Surface expression of CD66c is regulated at the gene transcription level, in contrast to previous reports.
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Background
Although expression of surface markers in acute lymphob-
lastic leukemia (ALL) parallels that of normal hematopoi-
etic precursors, several markers of myeloid lineage are
found on ALL lymphoblasts. This phenomenon is referred
to as "aberrant expression". The issue of the regulatory
mechanisms that allow it has been addressed repeatedly
throughout the recent 40 years [1,2]. Although several
hypotheses stressing either possible lineage indecisiveness
or genetic misprogramming have been raised, the phe-
nomenon is still not fully understood. We and others have
shown that the myeloid antigen CD66c is very frequently
aberrantly expressed in B-precursor ALL, however, a large
study showing its frequency in the light of other myeloid
antigens has been missing. CD66c expression was found
on cases of childhood and adult ALL in strong correlation
with nonrandom genetic changes (BCR/ABL positivity [3],
hyperdiploidy and TEL/AML1 negativity [4], reviewed in
[5]).
CD66c (CEACAM6, previously called Nonspecific cross-
reacting antigen, NCA 90/50 and KOR-SA3544 antigen) is
a member of the carcinoembryonic antigen family. This
heavily glycosylated molecule consists of two constant Ig-
like domains and one variable Ig-like domain and it is
anchored to the membrane via its glycosylphosphatidyli-
nositol (GPI). Within the hematopoietic system, CD66c
expression is limited to granulocytes and its precursors
[3,6], where it serves homotypic and heterotypic adhesion
[7], Ca2+ mediated signaling [8] and is markedly upregu-
lated from intracellular stores after activation [9].
It is also found in epithelia of various organs [7]. Upregu-
lation of CD66c is an early molecular event in transforma-
tion leading to colorectal tumors [10]. It was also
confirmed to inhibit anoikis (apoptotic response induced
in normal cells by inadequate or inappropriate adhesion
to substrate) in the in vitro model of carcinoma of colon
[11] and specific silencing of this gene led to decreased
metastatic potential in pancreatic adenocarcinoma [12].
Surprisingly, Sugita et al [13] reported intracellular pres-
ence of CD66c in all leukemic cell lines examined, regard-
less of surface presence or absence, with a different
antigen distribution in cytoplasm that determined surface
expression. They speculated that presence of an undis-
closed transporter would target this molecule to granules
and for surface expression, whereas surface CD66cneg cell
lines lack this transporter. This intriguing hypothesis
prompted us to test whether transcription of CEACAM6
gene and/or intracellular CD66c expression is always fol-
lowed by surface expression.
Uniqueness of aberrant expression of CD66c on malig-
nant lymphoblast is exploited for diagnosis of ALL and
follow-up of a minimal residual disease (MRD) using
flow cytometry [14,15]. To use a marker for a MRD assess-
ment a critical question must be addressed, whether the
aberrant expression is a stable property of the malignant
clone or whether it can be subject to immunophenotype
shift.
In the present study we set out to address the frequency of
CD66c molecule expression in childhood ALL, the regula-
tion of CD66c expression from gene transcription to cyto-
plasmic and surface expression, and we follow
immunophenotype stability from diagnosis to relapse.
We also discuss relevance of CD66c for prognosis
prediction.
Methods
Patients
The cohort of all Czech children (<18 years) diagnosed
with B-precursor ALL investigated in our reference labora-
tory from 1.5.1997 to 23.7.2004 was used for current
study (n = 381). Informed consent was obtained from
patients and/or their guardians. The presence of TEL/
AML1, BCR/ABL and MLL/AF4 fusion genes was detected
by two-round nested PCR, hyperdiploidy was assessed
using DNA index flow cytometric measurement as
described previously [4]. Patients' genotype and corre-
sponding surface CD66c expression is shown in Figure 1
(genotype available in 98% of patients). For intracellular
staining and FACS sorting, only samples with enough
material were selected.
Cell lines
Surface CD66c negative cell lines with typical transloca-
tion found in childhood ALL: TEL/AML1pos (REH) was
kindly provided by R. Pieters (University Hospital Rotter-
dam), MLL/AF4pos (RS4;11) translocation and with no
fusion (NALM-6) were obtained from German Cell Line
collection (DSMZ, Braunschweig, Germany)
Flow Cytometry
Flow cytometry immunophenotyping of bone marrow
(BM) aspirates was performed in at diagnosis and at
relapse. Routine immunophenotypic classification using
panel of monoclonal antibodies (moAbs) was performed
as described previously [4]. Briefly, BM samples were
stained with 2-, 3- and 4-color combinations of moAbs for
15 min in darkness, erythrocytes were lysed with NH4Cl-
containing lysing solution for 15 min, washed and data
were acquired using single FACS Calibur instrument
throughout the study (BD Biosciences, San Jose, CA, USA)
flow cytometer. Anti-CD66c (CEACAM6) moAb used in
all diagnostic and relapse measurements in this study was
clone KOR-SA3544 directly labeled to FITC (Immu-
notech, Marseille, France). Intracellular staining was per-
formed using Fix & Perm kit (Caltag, Burlingame, CA,BMC Cancer 2005, 5:38 http://www.biomedcentral.com/1471-2407/5/38
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USA) according to manufacturer's protocol. Acquired data
was analyzed with Cell Quest (BD Biosciences) or Flow Jo
(Tree Star, Ashland, OR, USA) software, lymphoblast gate
was drawn based on optical scatter and CD19pos blast
population was selected for further analysis.
Value of 20% was chosen as a threshold of positivity as
recommended by EGIL [16]. For robust prognostic signif-
icance testing, other threshold values were also tested as
indicated in results.
Cross-blocking of CD66c moAbs
Bone marrow samples of CD66c positive blasts were
stained with anti-CD66c moAb clone 9A6 (Genovac,
Freiburg, Germany) moAb for 15 min, erythrocytes were
lysed with NH4Cl-containing lysing solution for 15 min,
washed and sample was incubated with anti-CD66c
moAb KOR-SA3544 PE moAb conjugate.
Western blot
Samples containing 5 × 106 cells were lysed for 30 min at
4°C in 100 µl lysis buffer containing 20 mM Tris-HCl (pH
8.2), 100 mM NaCl, 50 mM NaF, 10 mM EDTA, 10 mM
pyrophosphate (Na4P2O7) and Complete Mini EDTA-Free
(protease inhibitor cocktail tablets, Roche Diagnostics,
Mannheim, Germany). Debris was sedimented by centrif-
ugation for 3 min at 13000 rpm, 0°C. Supernatants were
mixed with 100 µl 2× Laemmli's SDS-polyacrylamide gel
electrophoresis (PAGE) sample loading buffer, and
heated for 5 min at 100°C. Proteins were fractionated by
SDS-PAGE on 12.5% gels and electrophoretically trans-
ferred to PVDF membranes (Bio-Rad, Hercules, CA, USA).
Membranes were blocked for 1 h in PBS (pH 7.4) contain-
ing 0.5% Tween-20 and 5% nonfat dried milk. Blots were
then incubated for 1 h at room temperature with anti-
KOR-SA3544 (Immunotech, Marseille, France) or anti-
beta-actin (Sigma-Aldrich, Saint Louis, MO, USA) moAbs
and then developed using goat anti-mouse IgG (H+L)-
HRP conjugate (Bio-Rad). Immunoreactive material was
then revealed by enhanced chemiluminescence (ECL,
Amersham, Little Chalfont Buckinghamshire, UK) accord-
ing to the manufacturer's instructions.
Isolation of RNA and Real-Time Quantitative PCR analysis 
(RQ-PCR)
For RQ- PCR analysis, leukemic blasts were FACS sorted
using sorting option on FACS Calibur or on FACS Aria
instrument (1.1 × 104 - 4.7 × 105 cells from one patient).
Isolation of RNA from FACS-sorted cells was performed
using Trizol-reagent (Gibco BRL, Carlsbad, CA, USA)
according to manufacturer's instructions [17]. Comple-
mentary DNA was prepared using M-MLV Reverse Tran-
scriptase (Gibco) according to manufacturer instructions.
Glycogen (Gibco) 250 µg /mL was added when initial cell
number was lower than 105. Quality of cDNA was verified
by PCR on beta-2-microglobulin (B2M) housekeeping
gene.
RQ-PCR was performed in the LightCycler™ rapid thermal
cycler system (Roche Diagnostic GmbH, Mannheim, Ger-
many), according to manufacturer's instructions, using
SYBR green intercalating dye. CEACAM6 specific primers
3'-CGCCTTTGTACCAGCTGTAA and 5'-GCATGTCCCCT-
GGAAGGA designed by Baranov [18] were used for
CEACAM6 amplification and B2M specific primers 3'-
GATGCTGCTTACATGTCTCG 5'-CCAGCAGAGAAT-
GGAAAGTC [19]were used for total cDNA quantification.
PCR amplification was carried out in 1× reaction buffer
(20 mmol/L Tris-HCl, pH 8.4; 50 mmol/L KCl); and 2.0
mmol MgCl2 containing 200 µmol/L of each dNTP, 0.2
µmol/L of each primer, 5 µg bovine serum albumin per
reaction, and 1 U of Platinum Taq DNA polymerase (all
from Gibco) in a final reaction volume of 20 µL. For each
PCR reaction, 2 µL of cDNA template and 2 µl of SYBR
Green 5 × 10-4 (FMC BioProducts, Rockland, MA, USA)
fluorescent dye was included. The cycling conditions were
2.0 minutes at 95°C followed by 45 cycles of
Correlation of ALL genotype categories and percentage of  CD66c positivity Figure 1
Correlation of ALL genotype categories and percent-
age of CD66c positivity. Median percentage of CD66cpos 
blasts is listed below each genotype group. Data of consecu-
tive unselected patients with BCP ALL (n = 373) are shown.BMC Cancer 2005, 5:38 http://www.biomedcentral.com/1471-2407/5/38
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denaturation at 94°C for 5 seconds, annealing at 59°C for
30 seconds, and extension at 72°C for 15 seconds.
CEACAM6 and B2M gene were amplified separately from
the same cDNA, and all experiments were performed in
duplicate. Melting curve analysis was performed after each
run; in case of peak melting temperature shift, PCR prod-
ucts were verified on agarose gel electrophoresis.
Normalized CEACAM6 Expression (CEACAM6n)
Amplification and calibration curves were generated by
using affiliated software (LightCycler 3 data-analysis soft-
ware; version 3.5.28; Idaho Technology Inc., Salt Lake
City, UT, USA). A calibration curve for the B2M and
CEACAM6 housekeeping gene was generated using the
series of 10× diluted cDNA from peripheral blood granu-
locytes as a standard for both reactions. Crossing point
(Cp) value was calculated with LightCycler 3 software
using second derivative maximum method. CEACAM6n
value is relative and represents a ratio of CEACAM6 to
B2M (CEACAM6n = CEACAM6/ B2M). Standard cDNA
from granulocytes was assigned CEACAM6n value of 1,
the same aliquot of granulocytes cDNA was used through-
out of study.
Statistics
Statistical evaluation was done with Statview software,
(SAS Institute Inc, NC, USA). We used Fisher's exact test,
regression coefficient, Mann-Whitney test and Logrank
(Mantel-Cox) test as described in text.
Results
Frequency of CD66c and myeloid antigen (MyAg) 
expression
We selected 365 patient's samples obtained at diagnosis
of B-precursor ALL with available information on the
expression of MyAg CD13, CD15, CD33, CD65 and
CD66c. This subcohort represents 96% of all B-precursor
ALL diagnosed in the study period. The CD66c molecule
was expressed on 43% cases (Table 1, cases with >20%
positive blasts were considered positive). For the fraction
of positive cells and correlation with genotype see [5], of
note, 29% of patients expressed CD66c on more then
50% blasts. Comparison with other MyAg showed that
CD66c is more frequently expressed. Coexpression of
CD66c with other MyAg was not a usual finding (Table 1,
Figure 2). Expression of CD13, CD33 and CD65 tended to
be non-random (mutually exclusive) with CD66c (Table
1). Coexpression of CD66c with any 2 of the other MyAg
was found in fewer than 4 cases in each combination.
Interestingly, mutual relationship of other MyAg was ran-
dom, with the exception of CD13 and CD33 coexpression
(p < 0.0001) and CD15 and CD65 coexpression (p =
0.0002). The analysis was performed also at different cut-
off values (10, 30 and 50 %; data not shown). The same
or less significant correlations were also observed at differ-
ent cutoff values.
Cross-blocking of KOR-SA3544 clone with 9A6 clone
The moAb clone KOR-SA3544 was not included in
Human Leukocyte Differentiation Antigens workshop,
but was characterized by Sugita et al [13]. To prevent
ambiguous interpretation of our data we extended charac-
terization of KOR-SA3544 clone of CD66c moAb by
blocking experiments on CD66cpos blasts. Pretreatment of
cells with workshop-typed clone 9A6 moAb completely
blocked binding of KOR-SA3544 clone in all 9 leukemic
specimens and in granulocytes (data not shown).
Cytoplasmic presence of CD66c in ALL blasts
We have studied surface and cytoplasmic expression of
CD66c in 20 ALL diagnostic samples by flow cytometry.
In contrast to findings of Sugita et al [13], we have
detected CD66c exclusively in all 8 surface positive cases.
None of the 12 surface negative cases stained in cytoplasm
Table 1: Frequency of CD66c and myeloid antigen expression. Cases with >20% blasts are regarded positive, coexpression of CD66c 
and other MyAg is tested by Fisher's exact test.
Molecule No of cases (total = 365) Proportion [%] Coexpression with CD66c
CD66c 156 43
CD33 85 23
CD15 72 20
CD13 57 16
CD65 14 3.8
CD66c and CD33 21 5.8 mutually exclusive p = 0.002
CD66c and CD15 30 8.2 random NS
CD66c and CD13 9 2.5 mutually exclusive P < 0.0001
CD66c and CD65 2 0.55 mutually exclusive p = 0.029BMC Cancer 2005, 5:38 http://www.biomedcentral.com/1471-2407/5/38
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(Figure 3). The probable cause of the opposite finding in
several cases (lower percentage after permeabilization
than on surface) is a higher background after permeabili-
zation (isotypic control mean fluorescence intensity was
4.3 ± 2.0 and 9.7 ± 3.7 for surface and permeabilized
staining, respectively), which covers borderline events.
Transcription of CEACAM6 gene
To extend the above findings, we used Real-Time Quanti-
tative Reverse Transcription-PCR (RQ-RT-PCR) to quanti-
tatively assess presence of specific CEACAM6 mRNA. We
FACS-sorted CD19posCD66cneg or CD19posCD66cpos blast
cells for RQ-RT-PCR analysis. We didn't find significant
amount of CEACAM6 transcript in surface
CD66cneglymphoblasts, whereas CD66cpos cells contained
CEACAM6. When CD66cneg  and positive fraction was
FACS-sorted of heterogeneous specimens (lymphoblasts
partly positive for CD66c) the level of CEACAM6 was
observed higher in CD66cneg cells and lower in CD66cpos
cells as compared to uniform populations (Figure 4). In
one specimen (ALL patient with Down syndrome),
CEACAM6 wasn't increased in CD66cpos fraction.
Western blot
We further question the intracellular CD66c positivity in
surface CD66c negative cell lines. We performed Western
blot as described by Sugita et al. [13] on REH (TEL/
AML1pos) and RS4;11 (MLL/AF4pos) cell lines and found
no CD66c protein (Figure 5). Furthermore we found
NALM-6 (surface CD66cneg, no translocation) cell line
negative. Two BCR/ABL and four hyperdiploid (all surface
CD66cpos) diagnostic samples used as positive controls
were positive, with the similarly narrow band contrasting
to broad band detected in granulocytes (Figure 5), sug-
gesting different glycosylation in keeping with report by
Sugita.
Stability of surface expression from diagnosis to relapse
All relapsed patients up till 12/2003 with available infor-
mation on CD66c expression at diagnosis and at relapse
were used to assess stability of CD66c expression. Com-
parison of CD66c expression in 39 cases of relapsed child-
hood ALL cases to their immunophenotype at diagnosis
Graphical illustration of myeloid antigen positivity in child- hood B-precursor ALL Figure 2
Graphical illustration of myeloid antigen positivity in 
childhood B-precursor ALL. For each antigen, positive 
cases are represented by a colored form. The areas of the 
forms roughly correspond to the frequency of positive cases 
(observed numbers of patients are marked in red) while the 
shapes are constructed to illustrate the respective coexpres-
sions. An arbitrary cutoff value of 20% is used for all antigens. 
The CD66c positivity correlates with negativity of any of the 
following: CD33 (p = 0.002), CD13 (p < 0.0001) and CD65 
(p = 0.029). There was a significant correlation between 
CD33 and CD13 positivity (p < 0.0001) and between CD15 
and CD65 positivity (p = 0.0002) whereas the positivity of no 
other two antigens of the ones shown correlated significantly 
with each other. Total number of B-precursor cases illus-
trated is 365.
Relationship of surface and cytoplasmic expression of CD66c Figure 3
Relationship of surface and cytoplasmic expression of 
CD66c. Percentage of surface expression of CD66c in ALL 
blasts is plotted against cytoplasmic expression (after cell 
membrane permeabilization). Samples of 20 patients at ALL 
diagnosis are shown, 12 CD66c negative and 8 CD66c posi-
tive. Regression coefficient R2 = 0.927
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Transcription of CEACAM6 versus surface CD66c expression on sorted cells Figure 4
Transcription of CEACAM6 versus surface CD66c expression on sorted cells. FACSsorted CD66c surface negative 
(CD66cneg) or positive (CD66cpos) ALL lymphoblasts, five patients with heterogeneous CD66c expression were sorted into 
both CD66c negative and CD66c positive fraction (lines connect sorted fractions from the same specimen). Mann-Whitney 
test was used to compare groups (n = 32). CEACAM6n value is normalized to beta-2-microglobulin (see Methods).
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revealed that both negativity and positivity of this antigen
was retained from diagnosis to relapse (Figure 6; median
time to relapse 2.5y min 0.3y, max 5.3y). Although the
quantitative levels of CD66c expression differed in some
patients (median difference 0.0%, standard deviation
21%), no case of CD66c complete loss or gain was found
in our cohort.
Prognostic significance of CD66c expression
Only B-precursor ALL patients treated on the same ALL
BFM 95 treatment protocol [20] (n = 254) were evaluated
for prognostic impact. The prognosis did not differ for
cases with either CD66cpos blasts exceeding either 20%
(Figure 7) or any other cutoff value tested (5%, 10% and
50%, data not shown).
Next, we asked whether CD66c expression correlated with
the risk factors used in ALL BFM-95 protocol for stratifica-
tion into risk groups [21]. No difference in relapse free
survival (RFS) was noted when analyzed separately for
each risk group or higher and lower initial leukocytosis
(cutoff value: 2 × 104 cells per ml), age group or response
to prednisone (groups as in Table 2).
When analyzed with respect to a genotype, we found no
prognostic value of CD66c in any defined group (BCR/
ABLpos, TEL/AML1pos, hyperdiploid ALL and none of the
above-mentioned genetic changes, Figure 7 and Table 2).
Western blot of granulocytes, ALL samples of CD66c positive cases and surface CD66cneg cell lines with TEL/AML1pos  (REH), MLL/AF4pos (RS4;11) translocation and with no fusion (NALM-6) Figure 5
Western blot of granulocytes, ALL samples of CD66c positive cases and surface CD66cneg cell lines with TEL/AML1pos 
(REH), MLL/AF4pos (RS4;11) translocation and with no fusion (NALM-6).
Stability of CD66c from diagnosis to relapse Figure 6
Stability of CD66c from diagnosis to relapse. Each cir-
cle represents one patient (n = 39). Percentage of CD66cpos 
blasts at diagnosis is plotted against percentage of CD66cpos 
blasts at relapse. Regression line with 95% confidence R2 = 
0.755
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In contrast to the study by Hanenberg et al [22], there was
no correlation between initial leukocytosis and CD66c in
our cohort (Table 2).
Discussion
Our data on childhood B-precursor ALL show that CD66c
is more frequently expressed than the myeloid antigens
included in the standard immunophenotyping panels for
ALL. To our knowledge, CD66c is the most frequent mye-
loid marker in childhood ALL. This, together with the
tight correlations between CD66c and genotype [5],
makes CD66c a pertinent object of research on aberrant
expression regulation.
In line with the data from Sugita, we confirm the specifi-
city of KOR-SA3544 clone moAb for CD66c by CEACAM6
mRNA detection and by cross-blocking of KOR-SA3544
binding by representative 9A6 clone, that suggests a spa-
tial proximity of the two epitopes recognized. Further-
more we show that all CD66cpos ALL specimens show a
similar extent of glycosylation as cell lines analyzed by
Sugita, which differs from the extent of glycosylation in
granulocytes.
Since there is a strong correlation of ALL genotype and
CD66c expression, we hypothesized that surface CD66c
expression would be controlled by gene transcription
rather than by targeting to surface from intracellular stores
as proposed by Sugita [13]. In accordance with this, both
intracellular staining and Western blot failed to identify
cytoplasmic CD66c protein in any surface CD66cneg cells.
Down the same line, no CEACAM6 transcript was
Relapse free survival of cases with CD66cpos (blue line) or CD66cneg (red line) B-precursor ALL Figure 7
Relapse free survival of cases with CD66c pos (blue line) or CD66cneg(red line) B-precursor ALL. Unselected con-
secutive patients treated on ALL BFM95 protocol (median follow up 3.64 years). Since surface CD66c associates with geno-
type, separate analyses for distinct genotype subgroups are shown.
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detected in surface CD66cneg lymphoblasts. Overall our
data suggest that transcription is the checkpoint that leads
to surface expression, rather then the former model,
which proposed that all malignant lymphoblasts generate
the CD66c molecule but only some of them target it for
the cell membrane.
Interestingly, importance of this molecule was shown in a
model of colorectal carcinoma where transfection with
CEACAM6 inhibited anoikis (10), high CEACAM6 pre-
dicted high risk patients with resectable colorectal cancer
(9) and CEACAM6 gene silencing decreased resistance to
anoikis in vitro leading to inhibition of metastatic ability
in mouse model (11). Although the function of
CEACAM6 in ALL blasts is still unknown, this molecule's
function has been recently associated with pathogenesis
of other types of cancer in man [10-12,23,24]. Study of
anti-CEACAM6 immunotoxin-based therapy in mouse
model of pancreatic carcinoma was published recently
[25].
So far, prognostic significance of expression of myeloid
antigens CD13, CD14, CD33, CD65w, CD11b and CD15
has been studied with conflicting results (summarized in
[26]). As determined in our large cohort of patients
treated on ALL BFM 95 protocol, no prognostic signifi-
cance of CD66c could be revealed in general, nor when we
analyzed separate risk groups or TEL/AML1pos, BCR/ABL-
pos, hyperdiploid and other B-precursor ALL cases sepa-
rately. Furthermore, instability of aberrant expression was
reported for most myeloid markers (CD13, CD14, CD15,
CD33 and CD65).
Stability of expression is a major concern of flow cytomet-
ric studies of MRD. In present, use of multiple CD markers
is widely recommended to prevent MRD underestimation
due to the immunophenotype shift (discussed in
[15,27]). In current study we show for the first time that
CD66c expression stays qualitatively stable from diagno-
sis to relapse in all relapsed cases studied. This finding,
together with high frequency of CD66cpos cases, supports
inclusion of CD66c into a moAbs panels for MRD detec-
tion in patients positive for this CD marker at diagnosis.
However, anecdotal downregulation of CD66c expression
during chemotherapy has been observed [15], but has not
been methodically studied yet. Any temporary downregu-
lation might lead to falsely lower values of MRD measure-
ment – thus, it would be worthwhile to disclose whether
this phenomenon occurs regularly at certain points of
chemotherapy.
Mutual exclusiveness of MyAg expression as well as differ-
ent stability of CD66c compared to other MyAgs [28]
challenges the general practice of prognostic evaluation of
MyAgpos ALL cases as a group [26] and favors individual
Table 2: Correlation between risk factors and CD66c expression. The distribution of CD66cpos and CD66cneg cases (cutoff 20%) is 
shown. In addition, no difference was observed in the RFS of the risk-defined subsets based on the CD66c expression (log-rank test p-
value > 0.05 in all analyses). Only patients treated by a single ALL BFM-95 protocol are shown here (n = 254).
CD66cpos cases CD66cneg cases p-value (chi-square)
All patients 109 145 N/A
Prednisone poor responder 9 12 n.s.
Prednisone good responder 100 133
Initial leukocytosis = > 20 × 109/L 28 44 n.s.
Initial leukocytosis < 20 × 109/L 81 101
TEL/AML1 2 77 P < 0.0001
BCR/ABL 7 1
MLL/AF4 0 1
Hyperdiploid 55 7
Other genotype (not TEL/AML1, BCR/ABL, MLL/AF4 or hyperdiploidy) 45 59
Age 1–5 59 88 n.s.
Age >5 50 57
Standard risk group 40 58 n.s.
Intermediate risk group 54 72
High risk group 15 15BMC Cancer 2005, 5:38 http://www.biomedcentral.com/1471-2407/5/38
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evaluation of contribution/regulation of each MyAg for
blast cell.
Conclusion
CD66c presents some of the tightest associations with ALL
genotype. Although our findings indicate that CD66c is
unlikely to gain a practical importance as a prognosis
predictor, there are several reasons to focus on it in diag-
nostic and MRD studies. CD66c, apparently the most fre-
quently expressed aberrant antigen in childhood ALL, is
very useful in discriminating leukemic blasts from non-
malignant cells. Aberrant expression remains a puzzling
phenomenon that warrants further investigation. If it is
confirmed by techniques sensitive enough that the so
called "aberrant markers" are truly not expressed on any
subtle population of lymphoid precursors, there will be
an opportunity to find new targets for specific ALL therapy
(e.g. monoclonal antibodies against differently
glycosylated form of CD66c) that will spare the non-
leukemic precursors, thus reducing the treatment toxicity.
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